logo
Electronic Arts Reports Q4 and FY25 Results

Electronic Arts Reports Q4 and FY25 Results

Business Wire06-05-2025

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Electronic Arts Inc. (NASDAQ: EA) today announced preliminary financial results for its fourth quarter and fiscal year ended March 31, 2025.
'The incredible success of College Football and the enduring strength of FC drove another record year for EA SPORTS, while The Sims capped FY25 with a historic Q4,' said Andrew Wilson, CEO of Electronic Arts. 'As we look to the future, we're confident in our ability to execute across a deep pipeline — beginning this summer with the highly anticipated reveal of Battlefield, a pivotal step in delivering on our next generation of blockbuster entertainment.'
'Q4 marked a strong finish to FY25, with broad-based momentum across the portfolio positioning the business for accelerated growth,' said Stuart Canfield, CFO of Electronic Arts. 'As we enter FY26, we remain focused on disciplined execution as we build toward a slate of groundbreaking upcoming releases.'
Selected Operating Highlights and Metrics
Net bookings 1 for FY25 totaled $7.355 billion.
The EA SPORTS portfolio delivered another record net bookings year in FY25.
EA's American Football franchise exceeded expectations and reached over $1 billion in net bookings in FY25.
Celebrating its 25th birthday, The Sims franchise continues its strong momentum with double digit growth in the quarter.
In EA SPORTS FC, player monetization was up double digits, starting with the mid-January gameplay update.
Split Fiction has sold nearly 4 million units since its hugely successful launch in March.
Selected Financial Highlights and Metrics
Net revenue for FY25 was $7.463 billion.
Net cash provided by operating activities was $549 million for the quarter and $2.079 billion for the fiscal year.
EA repurchased 9.8 million shares for $1.375 billion during the quarter, bringing the total for the fiscal year to 17.6 million shares for $2.500 billion.
Dividend
EA has declared a quarterly cash dividend of $0.19 per share of the Company's common stock. The dividend is payable on June 18, 2025 to stockholders of record as of the close of business on May 28, 2025.
Business Outlook as of May 6, 2025
Fiscal Year 2026 Expectations
Operational outlook metrics:
Fiscal year 2026 net bookings is expected to be approximately $7.600 billion to $8.000 billion.
Year-over-year net bookings growth in fiscal year 2026 is expected to be driven by the EA SPORTS portfolio, The Sims, and the launches of Battlefield and skate., partially offset by approximately 5 points of weakness in catalog and Apex Legends.
The Company expects continued growth in live services, as well as the launch of new non-annual titles in fiscal year 2027.
Financial outlook metrics:
Net revenue is expected to be approximately $7.100 billion to $7.500 billion.
Change in deferred net revenue (online-enabled games) is expected to be approximately $500 million.
GAAP operating expenses are expected to be approximately $4.470 billion to $4.570 billion.
Year-over-year increases in expenses are largely attributable to costs related to Battlefield marketing.
Net income is expected to be approximately $795 million to $974 million.
Diluted earnings per share is expected to be approximately $3.09 to $3.79.
Operating cash flow is expected to be approximately $2.200 billion to $2.400 billion.
The Company estimates a share count of 257 million for purposes of calculating diluted earnings per share.
The Company intends to return at least 80% of free cash flow with stock repurchases and dividends through fiscal year 2027.
The Company reiterates its financial margin framework through fiscal year 2027 shared at its September 2024 Investor Day.
Q1 Fiscal Year 2026 Expectations – Ending June 30, 2025
Operational outlook metric:
Net bookings is expected to be approximately $1.175 billion to $1.275 billion.
Live services growth, excluding Apex Legends, is expected to be up low-single-digits year-over-year led by the EA SPORTS portfolio, offset by approximately 5 points of headwind from Apex Legends and 2 points of headwind from catalog.
Financial outlook metrics:
Net revenue is expected to be approximately $1.550 billion to $1.650 billion.
Change in deferred net revenue (online-enabled games) is expected to be approximately ($375) million.
GAAP operating expenses are expected to be approximately $1.110 billion to $1.120 billion.
Expenses in Q1 are impacted by continued investments in line with Q4 FY25, as well as costs associated with resource reprioritization.
Net income is expected to be approximately $125 million to $169 million.
Diluted earnings per share is expected to be approximately $0.49 to $0.66.
The Company estimates a share count of 255 million for purposes of calculating diluted earnings per share.
Fiscal Year Financial Highlights
Twelve Months Ended
M arch 31,
2025
2024
(in $ millions, except per share amounts)
Full game
2,002
2,015
Live services and other
5,461
5,547
Total net revenue
7,463
7,562
Net income
1,121
1,273
Diluted earnings per share
4.25
4.68
Operating cash flow
2,079
2,315
Value of shares repurchased
2,500
1,300
Number of shares repurchased
17.6
10.0
Cash dividend paid
199
205
Expand
Conference Call and Supporting Documents
Electronic Arts will host a conference call on May 6, 2025 at 2:00 pm PT (5:00 pm ET) to review its results for the fourth fiscal quarter and fiscal year ended March 31, 2025 and its outlook for the future. During the course of the call, Electronic Arts may disclose material developments affecting its business and/or financial performance. Listeners may access the conference call live through the following dial-in number (855) 761-5600 (domestic) or (646) 307-1097 (international), using the conference code 5939891 or via webcast at EA's IR Website at http://ir.ea.com.
EA has posted a slide presentation with a financial model of EA's historical results and guidance on EA's IR Website. EA will also post the prepared remarks and a transcript from the conference call on EA's IR Website.
A dial-in replay of the conference call will be available until May 13, 2025 at (800) 770-2030 (domestic) or (609) 800-9099 (international) using conference code 5939891. An audio webcast replay of the conference call will be available for one year on EA's IR Website.
Forward-Looking Statements
Some statements set forth in this release, including the information relating to EA's expectations under the heading 'Business Outlook as of May 6, 2025' and other information regarding EA's expectations contain forward-looking statements that are subject to change. Statements including words such as 'anticipate,' 'believe,' 'expect,' 'intend,' 'estimate,' 'plan,' 'predict,' 'seek,' 'goal,' 'will,' 'may,' 'likely,' 'should,' 'could' (and the negative of any of these terms), 'future' and similar expressions also identify forward-looking statements. These forward-looking statements are not guarantees of future performance and reflect management's current expectations. Our actual results could differ materially from those discussed in the forward-looking statements.
Some of the factors which could cause the Company's results to differ materially from its expectations include the following: sales of the Company's products and services; the Company's ability to develop and support digital products and services, including managing online security and privacy; outages of our products, services and technological infrastructure; the Company's ability to manage expenses; the competition in the interactive entertainment industry; governmental regulations; the effectiveness of the Company's sales and marketing programs; timely development and release of the Company's products and services; the Company's ability to realize the anticipated benefits of, and integrate, acquisitions; the consumer demand for, and the availability of an adequate supply of console hardware units; the Company's ability to predict consumer preferences and trends; the Company's ability to develop and implement new technology; foreign currency exchange rate fluctuations; economic and geopolitical conditions; changes in our tax rates or tax laws; and other factors described in Part II, Item 1A of Electronic Arts' latest Quarterly Report on Form 10-Q under the heading 'Risk Factors', as well as in other documents we have filed with the Securities and Exchange Commission, including our Annual Report on Form 10-K for the fiscal year ended March 31, 2024.​
These forward-looking statements are current as of May 6, 2025. Electronic Arts assumes no obligation to revise or update any forward-looking statement, except as required by law. In addition, the preliminary financial results set forth in this release are estimates based on information currently available to Electronic Arts.
While Electronic Arts believes these estimates are meaningful, they could differ from the actual amounts that Electronic Arts ultimately reports in its Annual Report on Form 10-K for the fiscal year ended March 31, 2025. Electronic Arts assumes no obligation and does not intend to update these estimates prior to filing its Form 10-K for the fiscal year ended March 31, 2025.
About Electronic Arts
Electronic Arts (NASDAQ: EA) is a global leader in digital interactive entertainment. The Company develops and delivers games, content and online services for Internet-connected consoles, mobile devices and personal computers.
In fiscal year 2025, EA posted GAAP net revenue of approximately $7.5 billion. Headquartered in Redwood City, California, EA is recognized for a portfolio of critically acclaimed, high-quality brands such as EA SPORTS FC™, Battlefield™, Apex Legends™, The Sims™, EA SPORTS™ Madden NFL, EA SPORTS™ College Football, Need for Speed™, Dragon Age™, Titanfall™, Plants vs. Zombies™ and EA SPORTS F1®. More information about EA is available at www.ea.com/news.
EA, EA SPORTS, EA SPORTS FC, Battlefield, Need for Speed, Apex Legends, The Sims, Dragon Age, Titanfall, and Plants vs. Zombies are trademarks of Electronic Arts Inc. John Madden, NFL, and F1 are the property of their respective owners and used with permission.
Results (in $ millions, except per share data)
The following table reports the variance of the actuals versus our guidance provided on February 4, 2025 for the three months ended March 31, 2025 plus a comparison to the actuals for the three months ended March 31, 2024.
Three Months Ended March 31,
Variance
Net revenue
Net revenue
1,757
138
1,895
1,779
GAAP-based financial data
Change in deferred net revenue (online-enabled games) 1
(238
)
142
(96
)
(113
)
Cost of revenue
Cost of revenue
310
58
368
357
GAAP-based financial data
Acquisition-related expenses
(10
)

(10
)
(29
)
Stock-based compensation
(4
)
1
(3
)
(2
)
Operating expenses
Operating expenses
1,117
15
1,132
1,188
GAAP-based financial data
Acquisition-related expenses
(20
)
3
(17
)
(72
)
Restructuring and related charges
(7
)
3
(4
)
(61
)
Stock-based compensation
(161
)
2
(159
)
(146
)
Income before tax
Income before tax
351
56
407
260
GAAP-based financial data
Acquisition-related expenses
30
(3
)
27
101
Change in deferred net revenue (online-enabled games) 1
(238
)
142
(96
)
(113
)
Restructuring and related charges
7
(3
)
4
61
Stock-based compensation
165
(3
)
162
148
Tax rate used for management reporting
19
%
19
%
19
%
Earnings per share
Basic
0.83
0.16
0.99
0.68
Diluted
0.82
0.16
0.98
0.67
Number of shares used in computation
Basic
262
(5
)
257
267
Diluted
264
(5
)
259
270
Expand
1 The change in deferred net revenue (online-enabled games) in the unaudited condensed consolidated statements of cash flows does not necessarily equal the change in deferred net revenue (online-enabled games) in the unaudited condensed consolidated statements of operations primarily due to the impact of unrecognized gains/losses on cash flow hedges.
Expand
ELECTRONIC ARTS INC. AND SUBSIDIARIES
Unaudited Condensed Consolidated Balance Sheets
(in $ millions)
March 31, 2025
March 31, 2024 2
ASSETS
Current assets:
Cash and cash equivalents
2,136
2,900
Short-term investments
112
362
Receivables, net
679
565
Other current assets
349
420
Total current assets
3,276
4,247
Property and equipment, net
586
578
Goodwill
5,376
5,379
Acquisition-related intangibles, net
293
400
Deferred income taxes, net
2,420
2,380
Other assets
417
436
TOTAL ASSETS
12,368
13,420
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable, accrued, and other current liabilities
1,359
1,276
Deferred net revenue (online-enabled games)
1,700
1,814
Senior notes, current, net
400

Total current liabilities
3,459
3,090
Senior notes, net
1,484
1,882
Income tax obligations
594
497
Other liabilities
445
438
Total liabilities
5,982
5,907
Stockholders' equity:
Common stock
3
3
Retained earnings
6,470
7,582
Accumulated other comprehensive loss
(87
)
(72
)
Total stockholders' equity
6,386
7,513
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY
12,368
13,420
Expand
2 Derived from audited consolidated financial statements.
Expand
ELECTRONIC ARTS INC. AND SUBSIDIARIES
Unaudited Condensed Consolidated Statements of Cash Flows
(in $ millions)
Three Months Ended
March 31,
Twelve Months Ended
March 31,
2025
2024
2025
2024
OPERATING ACTIVITIES
Net income
254
182
1,121
1,273
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation, amortization, accretion and impairment
79
149
356
404
Stock-based compensation
162
148
642
584
Change in assets and liabilities
Receivables, net
64
303
(115
)
119
Other assets
19
(38
)
40
148
Accounts payable, accrued, and other liabilities
29
(53
)
190
(208
)
Deferred income taxes, net
48
(6
)
(41
)
82
Deferred net revenue (online-enabled games)
(106
)
(105
)
(114
)
(87
)
Net cash provided by operating activities
549
580
2,079
2,315
INVESTING ACTIVITIES
Capital expenditures
(54
)
(51
)
(221
)
(199
)
Proceeds from maturities and sales of short-term investments
329
182
695
632
Purchase of short-term investments
(61
)
(180
)
(437
)
(640
)
Net cash provided by (used in) investing activities
214
(49
)
37
(207
)
FINANCING ACTIVITIES
Proceeds from issuance of common stock
35
34
78
77
Cash dividends paid
(48
)
(51
)
(199
)
(205
)
Cash paid to taxing authorities for shares withheld from employees
(23
)
(18
)
(234
)
(196
)
Common stock repurchases and excise taxes paid
(1,375
)
(325
)
(2,508
)
(1,300
)
Net cash used in financing activities
(1,411
)
(360
)
(2,863
)
(1,624
)
Effect of foreign exchange on cash and cash equivalents
8
(13
)
(17
)
(8
)
Change in cash and cash equivalents
(640
)
158
(764
)
476
Beginning cash and cash equivalents
2,776
2,742
2,900
2,424
Ending cash and cash equivalents
2,136
2,900
2,136
2,900
Expand
ELECTRONIC ARTS INC. AND SUBSIDIARIES
(in $ millions, except per share data)
Net revenue
Net revenue
1,779
1,660
2,025
1,883
1,895
7
%
GAAP-based financial data
Change in deferred net revenue (online-enabled games) 1
(113
)
(398
)
54
332
(96
)
Gross profit
Gross profit
1,422
1,397
1,569
1,427
1,527
7
%
Gross profit (as a % of net revenue)
80
%
84
%
78
%
76
%
81
%
GAAP-based financial data
Acquisition-related expenses
29
10
10
10
10
Change in deferred net revenue (online-enabled games) 1
(113
)
(398
)
54
332
(96
)
Stock-based compensation
2
4
4
3
3
Operating income
Operating income
234
364
384
377
395
69
%
Operating income (as a % of net revenue)
13
%
22
%
19
%
20
%
21
%
GAAP-based financial data
Acquisition-related expenses
101
27
27
26
27
Change in deferred net revenue (online-enabled games) 1
(113
)
(398
)
54
332
(96
)
Restructuring and related charges
61
6
52

4
Stock-based compensation
148
143
174
163
162
Net income
Net income
182
280
294
293
254
40
%
Net income (as a % of net revenue)
10
%
17
%
15
%
16
%
13
%
GAAP-based financial data
Acquisition-related expenses
101
27
27
26
27
Change in deferred net revenue (online-enabled games) 1
(113
)
(398
)
54
332
(96
)
Restructuring and related charges
61
6
52

4
Stock-based compensation
148
143
174
163
162
Tax rate used for management reporting
19
%
19
%
19
%
19
%
19
%
Diluted earnings per share
0.67
1.04
1.11
1.11
0.98
46
%
Number of shares used in computation
Basic
267
266
264
262
257
Diluted
270
268
266
265
259
Expand
1 The change in deferred net revenue (online-enabled games) in the unaudited condensed consolidated statements of cash flows does not necessarily equal the change in deferred net revenue (online-enabled games) in the unaudited condensed consolidated statements of operations primarily due to the impact of unrecognized gains/losses on cash flow hedges.
Expand
ELECTRONIC ARTS INC. AND SUBSIDIARIES
Unaudited Supplemental Financial Information and Business Metrics
(in $ millions)
QUARTERLY NET REVENUE PRESENTATIONS
Net revenue by composition
Full game downloads
265
190
475
446
367
38
%
Packaged goods
68
60
241
153
70
3
%
Full game
333
250
716
599
437
31
%
Live services and other
1,446
1,410
1,309
1,284
1,458
1
%
Total net revenue
1,779
1,660
2,025
1,883
1,895
7
%
Full game
19
%
15
%
35
%
32
%
23
%
Live services and other
81
%
85
%
65
%
68
%
77
%
Total net revenue %
100
%
100
%
100
%
100
%
100
%
GAAP-based financial data
Full game downloads
(37
)
(47
)
70
25
(27
)
Packaged goods
(37
)
(35
)
46
9
(26
)
Full game
(74
)
(82
)
116
34
(53
)
Live services and other
(39
)
(316
)
(62
)
298
(43
)
Total change in deferred net revenue (online-enabled games) by composition 1
(113
)
(398
)
54
332
(96
)
Net revenue by platform
Console
1,049
1,005
1,374
1,215
1,182
13
%
PC & Other
423
365
364
392
426
1
%
Mobile
307
290
287
276
287
(7
%)
Total net revenue
1,779
1,660
2,025
1,883
1,895
7
%
GAAP-based financial data
Console
(94
)
(328
)
108
275
(86
)
PC & Other
(10
)
(70
)
(37
)
33
(11
)
Mobile
(9
)

(17
)
24
1
Total change in deferred net revenue (online-enabled games) by platform 1
(113
)
(398
)
54
332
(96
)
Expand
1 The change in deferred net revenue (online-enabled games) in the unaudited condensed consolidated statements of cash flows does not necessarily equal the change in deferred net revenue (online-enabled games) in the unaudited condensed consolidated statements of operations primarily due to the impact of unrecognized gains/losses on cash flow hedges.
Expand
ELECTRONIC ARTS INC. AND SUBSIDIARIES
Unaudited Supplemental Financial Information and Business Metrics
(in $ millions)
Q4
Q1
Q2
Q3
Q4
YOY %
FY24
FY25
FY25
FY25
FY25
Change
CASH FLOW DATA
Investing cash flow
(49
)
(69
)
(46
)
(62
)
214
Investing cash flow - TTM
(207
)
(232
)
(215
)
(226
)
37
118
%
Financing cash flow
(360
)
(546
)
(402
)
(504
)
(1,411
)
Financing cash flow - TTM
(1,624
)
(1,688
)
(1,739
)
(1,812
)
(2,863
)
(76
%)
Operating cash flow
580
120
234
1,176
549
Operating cash flow - TTM
2,315
2,076
2,198
2,110
2,079
(10
%)
Capital expenditures
51
67
50
50
54
Capital expenditures - TTM
199
221
220
218
221
11
%
Free cash flow 3
529
53
184
1,126
495
Free cash flow 3 - TTM
2,116
1,855
1,978
1,892
1,858
(12
%)
Common stock repurchases and excise taxes paid
325
375
375
383
1,375
323
%
Cash dividends paid
51
50
51
50
48
(6
%)
DEPRECIATION
Depreciation expense
50
51
51
51
51
2
%
BALANCE SHEET DATA
Cash and cash equivalents
2,900
2,400
2,197
2,776
2,136
Short-term investments
362
366
366
379
112
Cash and cash equivalents, and short-term investments
3,262
2,766
2,563
3,155
2,248
(31
%)
Receivables, net
565
433
1,012
742
679
20
%
STOCK-BASED COMPENSATION
Cost of revenue
2
4
4
3
3
Research and development
104
101
122
119
115
Marketing and sales
14
12
16
14
14
General and administrative
28
26
32
27
30
Total stock-based compensation
148
143
174
163
162
RESTRUCTURING AND RELATED CHARGES
Restructuring
59
2
51
1
3
Office space reductions
2
4
1
(1
)
1
Total restructuring and related charges
61
6
52

4
Expand
3 Free cash flow is defined as Operating cash flow less Capital expenditures.
Expand
ELECTRONIC ARTS INC. AND SUBSIDIARIES
Unaudited Reconciliation of GAAP to Non-GAAP Financial Measures
(in $ millions)
The following table provides a reconciliation of non-GAAP operating income and margin to their most directly comparable GAAP financial measure for the twelve months ended March 31, 2025 plus a comparison to the actuals for the twelve months ended March 31, 2024.
Twelve Months Ended
March 31,
2025
2024
YOY % Change
Net revenue
7,463
7,562
(1%)
GAAP operating income
1,520
1,518

Acquisition-related expenses
107
218
Restructuring and related charges
62
64
Stock-based compensation
642
584
Non-GAAP operating income
2,331
2,384
(2%)
GAAP operating margin
20.4%
20.1%
Non-GAAP operating margin
31.2%
31.5%
Impact from change in deferred net revenue (online-enabled games)
(100 bps)
(120 bps)
Expand
ELECTRONIC ARTS INC. AND SUBSIDIARIES
Unaudited Reconciliation of GAAP to Non-GAAP Financial Measures
(in $ millions)
The following table provides a reconciliation of non-GAAP operating income and margin to their most directly comparable GAAP financial measure for the three months ended March 31, 2025 plus a comparison to the actuals for the three months ended March 31, 2024.
Three Months Ended
March 31,
2025
2024
YOY % Change
Net revenue
1,895
1,779
7%
GAAP operating income
395
234
69%
Acquisition-related expenses
27
101
Restructuring and related charges
4
61
Stock-based compensation
162
148
Non-GAAP operating income
588
544
8%
GAAP operating margin
20.8%
13.2%
Non-GAAP operating margin
31.0%
30.6%
Impact from change in deferred net revenue (online-enabled games)
(370 bps)
(470 bps)
Expand
ELECTRONIC ARTS INC. AND SUBSIDIARIES
GAAP Guidance to Non-GAAP Guidance
(in $ millions)
The following table provides GAAP to Non-GAAP reconciliation of the Company's FY26 guidance.
Twelve Months Ending March 31, 2026
A
B
C
Net revenue
7,100
to
7,500


7,100
to
7,500
500
Cost of revenue
1,475
to
1,515
(40)
(15)
1,420
to
1,460

Operating expense
4,470
to
4,570
(70)
(650)
3,750
to
3,850

Operating margin
16.3%
to
18.9%
150 bps
910 bps
27.2%
to
29.2%
480 bps to 440 bps
Income before provision for income taxes
1,136
to
1,391
110
665
1,911
to
2,166
500
Net income 4
795
to
974
Number of shares used in computation:
Diluted
257
Expand
4 The Company uses a tax rate of 19% internally to evaluate its operating performance and to forecast, plan and analyze future periods.
5 The mid-point of the range has been used for purposes of presenting reconciling items to operating margin.
Expand
Expand
4 The Company uses a tax rate of 19% internally to evaluate its operating performance and to forecast, plan and analyze future periods.
Expand
Non-GAAP Financial Measures
As a supplement to the Company's financial measures presented in accordance with U.S. Generally Accepted Accounting Principles ('GAAP'), the Company presents certain non-GAAP measures of financial performance, including non-GAAP operating margin and free cash flow. These non-GAAP financial measures should not be considered as a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP. In addition, these non-GAAP measures have limitations in that they do not reflect all of the items associated with the Company's results of operations as determined in accordance with GAAP. These non-GAAP financial measures do not reflect a comprehensive system of accounting and differ from GAAP measures with the same names and may differ from non-GAAP financial measures with the same or similar names that are used by other companies.
The non-GAAP financial measures exclude acquisition-related expenses, stock-based compensation, restructuring and related charges, and capital expenditures, as applicable in any given reporting period and our outlook. The Company may consider whether other significant items that arise in the future should be excluded from our non-GAAP financial measures. Management believes that these non-GAAP financial measures provide investors with additional useful information to better understand and evaluate the Company's operating results and future prospects because they exclude certain items that may not be indicative of the Company's core business, operating results, or future outlook. These non-GAAP financial measures, with further adjustments are used by management to understand ongoing financial and business performance.
The Company uses a tax rate of 19% internally to evaluate its operating performance and to forecast, plan, and analyze future periods. Accordingly, the Company applies the same tax rate to its management reporting financial results.
Investors are encouraged to review the related GAAP financial measures and the reconciliation of non-GAAP financial measures to their most directly comparable GAAP financial measure.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

WISeKey to Present at Maxim Tech Conference 'Discover the Innovations Reshaping Tomorrow' on June 3 at 8:30am ET
WISeKey to Present at Maxim Tech Conference 'Discover the Innovations Reshaping Tomorrow' on June 3 at 8:30am ET

Yahoo

time36 minutes ago

  • Yahoo

WISeKey to Present at Maxim Tech Conference 'Discover the Innovations Reshaping Tomorrow' on June 3 at 8:30am ET

WISeKey to Present at Maxim Tech Conference 'Discover the Innovations Reshaping Tomorrow' on June 3 at 8:30am ET Geneva, Switzerland, June 2, 2025 –WISeKey International Holding Ltd ('WISeKey') (SIX: WIHN, NASDAQ: WKEY), a leading global cybersecurity, blockchain, and IoT company, today announces that its management team will be presenting at the Maxim Group 2025 Virtual Tech Conference 'Discover the Innovations Reshaping Tomorrow.' WISeKey's fireside chat presentation is scheduled for June 3rd at 8:30 am ET. Investors can access the live presentation via the following link: During the presentation, Carlos Moreira, WISeKey's Founder and CEO, will provide a progress update on WISeKey's platform as it advances through the 'Year of Convergence,' integrating its subsidiaries' cybersecurity offerings: (WISeID) digital identification, (SEALSQ) post-quantum technology, (WISeSAT) satellite constellation, and (SEALCOIN) tokenization projects into the Company's revenue stream. About WISeKey WISeKey International Holding Ltd ('WISeKey', SIX: WIHN; Nasdaq: WKEY) is a global leader in cybersecurity, digital identity, and IoT solutions platform. It operates as a Swiss-based holding company through several operational subsidiaries, each dedicated to specific aspects of its technology portfolio. The subsidiaries include (i) SEALSQ Corp (Nasdaq: LAES), which focuses on semiconductors, PKI, and post-quantum technology products, (ii) WISeKey SA which specializes in RoT and PKI solutions for secure authentication and identification in IoT, Blockchain, and AI, (iii) WISeSat AG which focuses on space technology for secure satellite communication, specifically for IoT applications, (iv) Corp which focuses on trusted blockchain NFTs and operates the marketplace for secure NFT transactions, and (v) SEALCOIN AG which focuses on decentralized physical internet with DePIN technology and house the development of the SEALCOIN subsidiary contributes to WISeKey's mission of securing the internet while focusing on their respective areas of research and expertise. Their technologies seamlessly integrate into the comprehensive WISeKey platform. WISeKey secures digital identity ecosystems for individuals and objects using Blockchain, AI, and IoT technologies. With over 1.6 billion microchips deployed across various IoT sectors, WISeKey plays a vital role in securing the Internet of Everything. The company's semiconductors generate valuable Big Data that, when analyzed with AI, enable predictive equipment failure prevention. Trusted by the OISTE/WISeKey cryptographic Root of Trust, WISeKey provides secure authentication and identification for IoT, Blockchain, and AI applications. The WISeKey Root of Trust ensures the integrity of online transactions between objects and people. For more information on WISeKey's strategic direction and its subsidiary companies, please visit DisclaimerThis communication expressly or implicitly contains certain forward-looking statements concerning WISeKey International Holding Ltd and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of WISeKey International Holding Ltd to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. WISeKey International Holding Ltd is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. This press release does not constitute an offer to sell, or a solicitation of an offer to buy, any securities, and it does not constitute an offering prospectus within the meaning of the Swiss Financial Services Act ('FinSA'), the FinSa's predecessor legislation or advertising within the meaning of the FinSA. Investors must rely on their own evaluation of WISeKey and its securities, including the merits and risks involved. Nothing contained herein is, or shall be relied on as, a promise or representation as to the future performance of and Investor Contacts WISeKey International Holding LtdCompany Contact: Carlos MoreiraChairman & CEOTel: +41 22 594 3000info@ WISeKey Investor Relations (US) The Equity Group CatiTel: +1 212 836-9611 lcati@

Zealand Pharma submits Marketing Authorization Application to the European Medicines Agency for glepaglutide in short bowel syndrome
Zealand Pharma submits Marketing Authorization Application to the European Medicines Agency for glepaglutide in short bowel syndrome

Yahoo

time36 minutes ago

  • Yahoo

Zealand Pharma submits Marketing Authorization Application to the European Medicines Agency for glepaglutide in short bowel syndrome

Press release – No. 10 / 2025 Zealand Pharma submits Marketing Authorization Application to the European Medicines Agency for glepaglutide in short bowel syndrome Copenhagen, Denmark, June 2, 2025 – Zealand Pharma A/S (Nasdaq: ZEAL) ('Zealand') (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for glepaglutide, a long-acting GLP-2 analog, for the treatment of adult patients with short bowel syndrome (SBS). The submission of the MAA to the EMA for glepaglutide administered twice weekly for the treatment of SBS is based on results from a pivotal Phase 3 trial (EASE-1), supported by interim results from two ongoing long-term extension trials (EASE-2 and EASE-3) and results from a mechanistic trial (EASE-4). 'We are pleased to bring our potential best-in-class GLP-2 analog, glepaglutide, one step closer to patients in Europe living with short bowel syndrome with intestinal failure, who urgently need more effective and more convenient treatment options,' said David Kendall, MD, Chief Medical Officer of Zealand Pharma. 'We believe that glepaglutide, administered twice weekly, offers meaningful potential to reduce both the burden of parenteral support and the inconvenience of daily dosing required with the only currently available GLP-2 therapy. Looking ahead, we expect to initiate the EASE-5 Phase 3 trial in the second half of the year to obtain further confirmatory safety and efficacy data on the twice weekly dosing regimen, supporting regulatory submission in the U.S.' About glepaglutideGlepaglutide is a long-acting GLP-2 analog in development as a potential treatment option for short bowel syndrome (SBS). Glepaglutide is developed as a liquid product in an autoinjector designed for subcutaneous administration by twice weekly dosing, aimed to reduce, or eliminate, the need for parenteral support in people living with SBS. The U.S. Food and Drug Administration (FDA) has granted orphan drug designation for glepaglutide for the treatment of SBS. About the EASE Clinical Trial ProgramThe Phase 3 program, named EASE, is designed to evaluate the potential for glepaglutide to reduce or eliminate the need for parenteral support in SBS patients with intestinal failure. EASE-1 (NCT03690206) was a randomized, double-blind Phase 3 trial that enrolled a total of 106 SBS patients with intestinal failure who were dependent on parenteral support for at least three days per week. Patients were evenly randomized to receive treatment with 10 mg glepaglutide administered either once or twice weekly, or placebo. The primary endpoint in the trial was the absolute change in weekly parenteral support volume from baseline at 24 weeks. At 24 weeks, glepaglutide administered twice weekly significantly reduced the total weekly volume of PS by 5.13 liters/week, compared to a reduction of 2.85 liters/week in the placebo group (p=0.0039). When administered once weekly, glepaglutide treatment resulted in a reduction in weekly PS of 3.13 liters/week, however this did not achieve statistical significance. A total of 9 patients treated with glepaglutide were completely weaned off PS (achieving enteral autonomy), while no placebo-treated patients were able to discontinue PS. For patients treated with glepaglutide twice weekly, 14% of patients (n=5) achieved enteral autonomy. In total, 102 of 106 participating patients completed EASE-1, of which 96 continued into the ongoing two-year, long-term safety and efficacy extension trial, EASE-2. EASE-2 (NCT03905707) is a randomized, double-blind trial in which SBS patients continued their randomly assigned treatment from EASE-1 with glepaglutide 10 mg once- or twice-weekly. Patients who received placebo in EASE-1 were re-randomized to treatment with either glepaglutide 10 mg once- or twice-weekly. In an interim analysis conducted after at least six months of treatment, clinical response to glepaglutide across the key efficacy endpoints was generally maintained or showed continued improvement, including additional patients on both doses weaning off PS. Patients who complete EASE-2 are eligible to participate in EASE-3 (NCT04881825), evaluating glepaglutide administered once weekly using an autoinjector. An interim analysis of EASE-3, conducted with the first 57 patients rolled over from EASE 2, showed that the reduction in prescribed PS was generally maintained. EASE-4 (NCT04991311) was a Phase 3b trial to assess mechanistic effects of glepaglutide on intestinal fluid and energy uptake. The trial provides evidence of the pharmacodynamic effects of glepaglutide in improving intestinal absorption. In the second half of 2025, Zealand Pharma expects to initiate EASE-5, a single Phase 3 clinical trial that is anticipated to provide further confirmatory evidence for a regulatory submission in the U.S. About Zealand Pharma A/SZealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. The company has development partnerships with a number of pharma companies as well as commercial partnerships for its marketed products. Zealand was founded in 1998 and is headquartered in Copenhagen, Denmark, with a presence in the United States. For more information about Zealand's business and activities, please visit Forward looking statementsThis press release contains 'forward-looking statements', as that term is defined in the Private Securities Litigation Reform Act of 1995 in the United States, as amended, even though no longer listed in the United States this is used as a definition to provide Zealand Pharma's expectations or forecasts of future events regarding the research, development and commercialization of pharmaceutical products, the timing of the company's pre-clinical and clinical trials and the reporting of data therefrom. These forward-looking statements may be identified by words such as 'aim,' 'anticipate,' 'believe,' 'could,' 'estimate,' 'expect,' 'forecast,' 'goal,' 'intend,' 'may,' 'plan,' 'possible,' 'potential,' 'will,' 'would' and other words and terms of similar meaning. You should not place undue reliance on these statements, or the scientific data presented. The reader is cautioned not to rely on these forward-looking statements. Such forward-looking statements are subject to risks, uncertainties and inaccurate assumptions, which may cause actual results to differ materially from expectations set forth herein and may cause any or all of such forward-looking statements to be incorrect, and which include, but are not limited to, unexpected costs or delays in clinical trials and other development activities due to adverse safety events, patient recruitment or otherwise; unexpected concerns that may arise from additional data, analysis or results obtained during clinical trials; our ability to successfully market both new and existing products; changes in reimbursement rules and governmental laws and related interpretation thereof; government-mandated or market-driven price decreases for our products; introduction of competing products; production problems at third party manufacturers; dependency on third parties, for instance contract research or development organizations; unexpected growth in costs and expenses; our ability to affect the strategic reorganization of our businesses in the manner planned; failure to protect and enforce our data, intellectual property and other proprietary rights and uncertainties relating to intellectual property claims and challenges; regulatory authorities may require additional information or further studies, or may reject, fail to approve or may delay approval of our drug candidates or expansion of product labeling; failure to obtain regulatory approvals in other jurisdictions; exposure to product liability and other claims; interest rate and currency exchange rate fluctuations; unexpected contract breaches or terminations; inflationary pressures on the global economy; and political uncertainty. If any or all of such forward-looking statements prove to be incorrect, our actual results could differ materially and adversely from those anticipated or implied by such statements. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from our expectations in any forward-looking statement. All such forward-looking statements speak only as of the date of this company announcement and are based on information available to Zealand Pharma as of the date of this announcement. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. Information concerning pharmaceuticals (including compounds under development) contained within this material is not intended as advertising or medical advice. ContactsAdam Lange (Investors)Vice President, Investor Relationsalange@ Neshat Ahmadi (Investors)Investor Relations Managerneahmadi@ Anna Krassowska, PhD (Investors and Media)Vice President, Investor Relations & Corporate Communicationsakrassowska@

China Liberal Education announces suspension of Nasdaq trading
China Liberal Education announces suspension of Nasdaq trading

Business Insider

time3 hours ago

  • Business Insider

China Liberal Education announces suspension of Nasdaq trading

China Liberal Education (CLEU) announced that on May 30, 2025, the Company received notice from The Nasdaq Stock Market LLC that the Company's securities will be suspended from trading on Nasdaq effective June 3, 2025. The suspension is due to the Company's failure to submit a request for an extended stay or otherwise address the delinquency in filing its annual report on Form 20-F for the fiscal year ended December 31, 2024, in its written submissions to the Nasdaq Hearings Panel. Confident Investing Starts Here:

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store